RIA Advisory Group LLC Has $325,000 Stock Position in Johnson & Johnson $JNJ

RIA Advisory Group LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 95.2% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,754 shares of the company’s stock after selling 34,767 shares during the period. RIA Advisory Group LLC’s holdings in Johnson & Johnson were worth $325,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Abich Financial Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $26,000. Clayton Financial Group LLC acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $28,000. Evolution Wealth Management Inc. acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $27,000. Semmax Financial Advisors Inc. boosted its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the period. Finally, Turning Point Benefit Group Inc. acquired a new position in shares of Johnson & Johnson in the third quarter valued at $41,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Timothy Schmid sold 1,322 shares of the company’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,142 shares of company stock valued at $7,360,528 in the last ninety days. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on JNJ. TD Cowen raised their target price on shares of Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. The Goldman Sachs Group reissued a “buy” rating and issued a $250.00 price target on shares of Johnson & Johnson in a report on Thursday, January 22nd. Barclays raised their price objective on shares of Johnson & Johnson from $217.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Thursday. Bank of America reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. Finally, Daiwa Securities Group increased their target price on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $236.91.

Johnson & Johnson Trading Up 0.2%

Shares of JNJ stock opened at $237.76 on Friday. The stock has a market cap of $572.68 billion, a P/E ratio of 21.52, a price-to-earnings-growth ratio of 2.34 and a beta of 0.34. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The stock has a 50 day simple moving average of $234.59 and a 200 day simple moving average of $207.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The firm had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s payout ratio is 47.06%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval of Icotyde opens a new, convenient oral IL‑23R treatment for moderate‑to‑severe plaque psoriasis — a potential multi‑billion‑dollar growth driver that directly expands J&J’s immunology portfolio and pressures injectable rivals. FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
• Positive Sentiment: HSBC raised its J&J price target to $280 and reiterated a Buy, citing healthcare strength — a clear bullish signal that can support further upside. HSBC Raises Johnson & Johnson (NYSE:JNJ) Price Target to $280.00
• Positive Sentiment: Morgan Stanley and other analysts continue to back J&J’s growth outlook around Icotyde (Morgan Stanley kept a Buy and $262 PT), reinforcing bullish institutional sentiment. Early Icotyde Approval Strengthens Johnson & Johnson’s Immunology Growth Outlook and Multi‑Billion‑Dollar Potential
• Positive Sentiment: Positive analyst/commentary pieces (e.g., The Motley Fool) argue J&J’s diversified franchises and new drugs justify a buy-and-hold stance, supporting longer‑term investor interest. 2 Reasons to Buy Johnson & Johnson Stock Like There’s No Tomorrow
• Neutral Sentiment: Barclays raised its target to $234 but kept an Equal‑Weight rating, implying limited near‑term upside from that shop and signaling mixed views across brokers. Benzinga
• Neutral Sentiment: Online investor interest and searches for JNJ have spiked (Zacks notes heavy attention), which can increase volatility but doesn’t guarantee direction. Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
• Neutral Sentiment: General dividend-planning content (e.g., pieces on how much to invest to get $100k in dividends) may drive some investor interest in JNJ’s yield, but it’s not a company‑specific catalyst. How Much Do you Need To Invest to Make $100k On Dividends Right Now?
• Negative Sentiment: Market/macro skepticism is limiting upside: commentators like Jim Cramer note J&J “should have gone higher” but broader stagflation concerns and a tough tape are keeping buyers cautious, which can cap short‑term gains. Jim Cramer on Johnson & Johnson: “It Should Have Gone Higher, But It Just Shows You How Hard It Is to Buck Stagflation Theories”
• Negative Sentiment: Recent short-term weakness (coverage noting a recent slide) highlights vulnerability to market rotation and headline-driven volatility despite fundamental wins. Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.